Targets › AP4M1
1 program from 1 company in 3 trials: 2 Phase 1, 1 Phase 3; Neurology; next expected readout Oct 2028.
Component of the adaptor protein complex 4 (AP-4). Adaptor protein complexes are vesicle coat components involved both in vesicle formation and cargo selection. (UniProt, O00189)
Open in Phaseline: the race on AP4M1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Elpida Therapeutics SPC | MELPIDA Recombinant adeno-associated virus serotype 9 (AAV9) encoding codon-optimized human AP4M1 | AP4M1 | Phase 3 | Hereditary Spastic Paraplegia Type 50; Spasticity, Muscle; Spastic Paraplegia Type 50 | Oct 2028 |
Hereditary Spastic Paraplegia Type 50 (1) Spasticity, Muscle (1) Spastic Paraplegia Type 50 (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.